Rafferty Asset Management LLC Has $3.32 Million Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Rafferty Asset Management LLC increased its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 90.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 172,960 shares of the company's stock after purchasing an additional 82,309 shares during the period. Rafferty Asset Management LLC owned about 0.22% of Viridian Therapeutics worth $3,316,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Voya Investment Management LLC lifted its holdings in shares of Viridian Therapeutics by 5.1% in the fourth quarter. Voya Investment Management LLC now owns 21,397 shares of the company's stock valued at $410,000 after purchasing an additional 1,038 shares in the last quarter. Tudor Investment Corp ET AL increased its holdings in shares of Viridian Therapeutics by 3.0% in the 4th quarter. Tudor Investment Corp ET AL now owns 38,367 shares of the company's stock valued at $735,000 after purchasing an additional 1,106 shares during the period. R Squared Ltd purchased a new stake in shares of Viridian Therapeutics in the fourth quarter worth approximately $26,000. Summit Investment Advisors Inc. boosted its holdings in shares of Viridian Therapeutics by 24.7% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock worth $147,000 after purchasing an additional 1,516 shares during the period. Finally, AlphaQuest LLC grew its position in Viridian Therapeutics by 119.0% during the fourth quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock valued at $54,000 after purchasing an additional 1,519 shares in the last quarter.

Viridian Therapeutics Stock Up 0.1%

NASDAQ VRDN traded up $0.01 during trading on Thursday, hitting $13.67. 568,146 shares of the company traded hands, compared to its average volume of 1,191,922. Viridian Therapeutics, Inc. has a 12 month low of $9.90 and a 12 month high of $27.20. The business has a fifty day simple moving average of $13.25 and a 200 day simple moving average of $16.99. The company has a market capitalization of $1.12 billion, a P/E ratio of -3.17 and a beta of 0.57. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.87) earnings per share for the quarter, beating analysts' consensus estimates of ($0.95) by $0.08. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The business had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.16 million. The firm's revenue was up .0% compared to the same quarter last year. As a group, sell-side analysts predict that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. JMP Securities cut their target price on shares of Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a research report on Wednesday, May 7th. The Goldman Sachs Group cut their price objective on Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Needham & Company LLC reissued a "buy" rating and set a $36.00 price objective on shares of Viridian Therapeutics in a research report on Tuesday. Royal Bank of Canada dropped their target price on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $34.00 price target on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $36.70.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.